Last reviewed · How we verify
Trastuzumab Emtansine for Injection
Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.
Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them. Used for Adjuvant treatment of HER2-positive breast cancer, Treatment of HER2-positive breast cancer, Treatment of HER2-positive gastric cancer.
At a glance
| Generic name | Trastuzumab Emtansine for Injection |
|---|---|
| Sponsor | Shanghai Miracogen Inc. |
| Drug class | HER2-targeting antibody-drug conjugate |
| Target | HER2 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Trastuzumab emtansine is a monoclonal antibody-drug conjugate that binds to the HER2 protein on the surface of cancer cells. Once bound, it releases a toxic compound called DM1, which kills the cancer cells.
Approved indications
- Adjuvant treatment of HER2-positive breast cancer
- Treatment of HER2-positive breast cancer
- Treatment of HER2-positive gastric cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Abdominal pain
- Infusion-related reactions
- Hypertension
- Headache
- Dizziness
- Muscle pain
- Cough
Key clinical trials
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (PHASE1, PHASE2)
- ATEMPT 2.0: Adjuvant T-DM1 vs TH (PHASE2)
- Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas (PHASE2)
- Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (PHASE2)
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab Emtansine for Injection CI brief — competitive landscape report
- Trastuzumab Emtansine for Injection updates RSS · CI watch RSS
- Shanghai Miracogen Inc. portfolio CI